NVO vs PFE: six-factor score, head to head
How Novo Nordisk A/S and Pfizer Inc.compare on Tapeline’s published six-factor composite score. Descriptive only — a rules-based reading of each name, not a recommendation.
Today, NVO scores 45 and PFE scores 67on Tapeline’s six-factor composite. PFE carries the higher composite score today. Here’s how the six factors line up.
| Factor | NVO | PFE |
|---|---|---|
| Trend | 39 | 89 |
| Relative Strength | 18 | 49 |
| Fundamentals | 92 | 58 |
| Smart Money | — | 88 |
| Macro | 50 | 50 |
| Momentum | 27 | 55 |
relative-strength factor in the bottom band vs the sector. trend factor in the bottom band of its score and fundamentals factor near the top of its range.
trend factor near the top of its range; smart-money factor above the score midpoint; macro factor above the midpoint for the current regime.
The Tapeline Score is a descriptive, rules-based measure for information only — not investment advice or a recommendation to buy or sell. See the six-factor method and the public scorecard.
More comparisons
FAQ
- How do NVO and PFE compare on Tapeline?
- Tapeline scores NVO 45/100 and PFE 67/100 on its published six-factor composite score (trend, relative strength, fundamentals, smart money, macro, momentum). The page breaks the two scores down factor by factor.
- Which has the higher Tapeline score, NVO or PFE?
- PFE has the higher composite score today (45 vs 67). The score is a descriptive measure, not a recommendation — see the per-factor breakdown above.
- Is this investment advice?
- No. Tapeline publishes a descriptive, rules-based six-factor score for information only. It is not a recommendation to buy or sell, and every top pick is back-checked publicly at /scorecard.